Lin BioScience, Inc. (TPEX:6696)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
701.00
+16.00 (2.34%)
Aug 5, 2026, 2:05 PM CST

Lin BioScience Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
------
Revenue Growth
------
Gross Profit
------
Operating Income
-2,857-2,857-1,458-1,097-445.13-338.28
Net Income
-1,363-1,363-744.27-687.19-313.52-434.7
Earnings Per Share
-16.60-16.60-9.47-9.29-4.37-6.32
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
16,29316,2935,2083,2611,645806.85
Total Debt
22.8122.8133.9942.8746.52.24
Net Cash (Debt)
16,27016,2705,1743,2181,599804.61
Net Cash Growth
213.23%214.43%60.78%101.30%98.70%-25.99%
Net Cash Per Share
198.15198.1565.8343.5022.2911.70

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1,441-1,441-1,019-1,013-361.01-289.84
Capital Expenditures
-7.2-7.2-5.82-1.97-22.38-2.12
Free Cash Flow
-1,449-1,449-1,025-1,015-383.4-291.96
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
------
Profit Margin
------
FCF Margin
------

Valuation

Selected indicators aren't available for this stock.